CHMP Favors EU Approval of Evrysdi as 1st Oral, At-home SMA Treatment

CHMP Favors EU Approval of Evrysdi as 1st Oral, At-home SMA Treatment

288565

CHMP Favors EU Approval of Evrysdi as 1st Oral, At-home SMA Treatment

Evrysdi (risdiplam) has been recommended for approval in the European Union (EU) to treat spinal muscular atrophy (SMA) patients, ages 2 months and older, with a clinical diagnosis of type 1, 2, or 3, or with one to four copies of the SMN2 “backup” gene. “Our close partnership with the SMA community has enabled the development of the first ‘at-home’ treatment for SMA in infants, children and adults with varying levels of disease severity, the…

You must be logged in to read/download the full post.